Joshua Xu

Dr. Joshua Xu

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2023 in Blood Cancer Discovery
Verified
Journal Article
Open access
PDF file
AVAna Vujovic
Ana Vujovic
LRLaura de Rooij
Laura de Rooij
ACAva Keyvani Chahi
Ava Keyvani Chahi
HCHe Tian Chen
He Tian Chen
BYBrian A. Yee
Brian A. Yee
KHKristin J. Hope
Kristin J. Hope
Acute myeloid leukemia (AML) is fueled by leukemic stem cells (LSC) whose determinants are challenging to discern from hematopoietic stem cells (HSC) or uncover by approaches focused on general cell properties. We have identified a set of RNA-binding proteins (RBP) selectively enriched in human AML LSCs. Using an in vivo two-step CRISPR-Cas9 screen to assay stem cell functionality, we found 32 RBPs essential for LSCs in MLL-AF9;NrasG12D AML. Loss-of-function approaches targeting key hit RBP ELAVL1 compromised LSC-driven in vivo leukemic reconstitution, and selectively depleted primitive malignant versus healthy cells. Integrative multiomics revealed differentiation, splicing, and mitochondrial metabolism as key features defining the leukemic ELAVL1–mRNA interactome with mitochondrial import protein, TOMM34, being a direct ELAVL1-stabilized target whose repression impairs AML propagation. Altogether, using a stem cell–adapted in vivo CRISPR screen, this work demonstrates pervasive reliance on RBPs as regulators of LSCs and highlights their potential as therapeutic targets in AML. Significance: LSC-targeted therapies remain a significant unmet need in AML. We developed a stem-cell–adapted in vivo CRISPR screen to identify key LSC drivers. We uncover widespread RNA-binding protein dependencies in LSCs, including ELAVL1, which we identify as a novel therapeutic vulnerability through its regulation of mitochondrial metabolism. This article is highlighted in the In This Issue feature, p. 171

24 January 2024 in Journal of Reconstructive Microsurgery
Verified
Journal Article
Closed access
PDF file
JXJoshua Xu
Joshua Xu
XZXi Ming Zhu
Xi Ming Zhu
KNKimberly C. Ng
Kimberly C. Ng
MAMuayyad M. Alhefzi
Muayyad M. Alhefzi
RARonen Avram
Ronen Avram
CCChristopher J. Coroneos
Christopher J. Coroneos
Background Autologous breast reconstruction offers superior long-term patient reported outcomes compared with implant-based reconstruction. Universal adoption of free tissue transfer has been hindered by procedural complexity and long operative time with microsurgery. In many specialties, co-surgeon (CS) approaches are reported to decrease operative time while improving surgical outcomes. This systematic review and meta-analysis synthesizes the available literature to evaluate the potential benefit of a CS approach in autologous free tissue breast reconstruction versus single-surgeon (SS). Methods A systematic review and meta-analysis was conducted using PubMed, Embase, and MEDLINE from inception to December 2022. Published reports comparing CS to SS approaches in uni- and bilateral autologous breast reconstruction were identified. Primary outcomes included operative time, postoperative outcomes, processes of care, and financial impact. Risk of bias was assessed and outcomes were characterized with effect sizes. Results Eight retrospective studies reporting on 9,425 patients were included. Compared with SS, CS approach was associated with a significantly shorter operative time (SMD −0.65, 95% confidence interval [CI] −1.01 to −0.29, p < 0.001), with the largest effect size in bilateral reconstructions (standardized mean difference [SMD] −1.02, 95% CI −1.37 to −0.67, p < 0.00001). CS was also associated with a significant decrease in length of hospitalization (SMD −0.39, 95% CI −0.71 to −0.07, p = 0.02). Odds of flap failure or surgical complications including surgical site infection, hematoma, fat necrosis, and reexploration were not significantly different. Conclusion CS free tissue breast reconstruction significantly shortens operative time and length of hospitalization compared with SS approaches without compromising postoperative outcomes. Further research should model processes and financial viability of its adoption in a variety of health care models.

18 June 2026 in Blood
Verified
Journal Article
Open access
HCHe Tian Tony Chen
He Tian Tony Chen
PJPratik Joshi
Pratik Joshi
SCSeverine Cathelin
Severine Cathelin
STSoheil Jahangiri Tazehkand
Soheil Jahangiri Tazehkand
SASaeer A Adeel
Saeer A Adeel
KHKristin Hope
Kristin Hope
Myelodysplastic neoplasms (MDS) feature hematopoietic deficits driven in part by transcript splicing abnormalities. Thus far, such disease-driving transcripts have been identified in association with specific splicing factor mutations. However, conserved aberrant splicing-derived transcripts that drive MDS independently of mutational status remain poorly studied despite representing global therapeutic targets. Here, we characterize an MDS-associated MBD1 isoform (MBD1-L) as a novel member of this class of transcripts. Rather than originating from a mutant splicing factor, the abnormal production of MBD1-L is driven by reduced WTAP expression in MDS. Overexpression of MBD1-L in healthy human HSPCs recapitulates archetypal MDS defects, including reduced terminal GLYA+ erythroid differentiation, suppressed cell cycling and impaired in vivo reconstitution capacity during increased hematopoietic demand in xenotransplantation assays. An integrated multiomics approach assessing DNA binding of MBD1 isoforms, and resulting changes in chromatin accessibility, histone mark deposition and transcriptional changes, revealed that these defects arise from an isoform-specific switching of MBD1's binding behavior. The MBD1-L isoform refocuses MBD1-L's heterochromatin-promoting activity from methylated to unmethylated CpGs and thus enacting broad downregulation of CpG-rich promoters as well as secondary epigenetic effects mediated by its downstream target BCOR. Remarkably, we also find that directly reversing abnormal MBD1 splicing across a broad range of primary human MDS samples using nanoparticle-encapsulated ASOs enhances in vitro erythroid differentiation, supporting the utility of RNA therapies for MDS treatment. Thus, our findings demonstrate MBD1-L to be a global, disease-driving splice variant across MDS, and illustrate the potential for RNA-based therapies in the broad treatment of MDS.

16 September 2024
Verified
Other
Open access
PDF file
AVAna Vujovic
Ana Vujovic
LRLaura de Rooij
Laura de Rooij
ACAva Keyvani Chahi
Ava Keyvani Chahi
HCHe Tian Chen
He Tian Chen
BYBrian A. Yee
Brian A. Yee
KHKristin J. Hope
Kristin J. Hope
Supplemental Figure S3 shows the generation of the bcCML mouse model and the effects of ELAVL1 on normal bone marrow in vivo.

16 September 2024
Verified
Other
Open access
PDF file
AVAna Vujovic
Ana Vujovic
LRLaura de Rooij
Laura de Rooij
ACAva Keyvani Chahi
Ava Keyvani Chahi
HCHe Tian Chen
He Tian Chen
BYBrian A. Yee
Brian A. Yee
KHKristin J. Hope
Kristin J. Hope
Supplemental Figure S1 shows expression of RBPs in healthy HSPCs and RN2c cells, sgRNA drop out dynamics in primary and secondary transplants, the molecular functions and biological processes associated with the hit RBPs and their gene essentialities.

16 September 2024
Verified
Other
Open access
PDF file
AVAna Vujovic
Ana Vujovic
LRLaura de Rooij
Laura de Rooij
ACAva Keyvani Chahi
Ava Keyvani Chahi
HCHe Tian Chen
He Tian Chen
BYBrian A. Yee
Brian A. Yee
KHKristin J. Hope
Kristin J. Hope
Supplemental Figure S1 shows expression of RBPs in healthy HSPCs and RN2c cells, sgRNA drop out dynamics in primary and secondary transplants, the molecular functions and biological processes associated with the hit RBPs and their gene essentialities.